Comparing next treatments for juvenile arthritis after a first biologic
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study tests different arthritis medications given in sequence for children and young adults with polyarticular JIA who did not get enough relief from a first TNF inhibitor. It aims to find which next treatment works best and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child must be between 2 and 21 years old and weigh at least 22 pounds (10 kg).
- The arthritis must affect multiple joints (called polyarticular JIA).
- You must have moderate to severe disease activity despite taking a TNF inhibitor (like etanercept or adalimumab) for at least 2 months.
- You can use low-dose steroids (like prednisone) only if the dose is stable for at least 2 weeks.
- You cannot have ever taken more than one TNF inhibitor, or any other biologic (like abatacept) or JAK inhibitor (like tofacitinib).
- You cannot have certain conditions, including inflammatory bowel disease, psoriasis, active uveitis, or a history of cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial studies how well upadacitinib (a pill) and tocilizumab (a shot/IV medicine) improve symptoms and inflammation in children with active systemic juvenile idiopathic arthritis (sJIA). It also looks at side effects and how these medicines move through the body.
This study tests two drugs—risankizumab and adalimumab—to see which is safer and works better for children with active psoriatic arthritis. It's for kids who have not been helped enough by standard disease-modifying drugs.
This trial tests whether children with juvenile idiopathic arthritis (JIA) who have been doing well for over a year can safely reduce their medications. The goal is to find the best way to keep arthritis under control while avoiding unnecessary treatments.
This Phase 3 study tests whether children with early juvenile idiopathic arthritis do better by starting with one treatment approach and adjusting (stepping up or stepping down) based on how their arthritis responds. It may help find the safest, most effective long-term plan for controlling symptoms with fewer side effects.
This study is for children and teens with inflammatory bowel disease (Crohn's, colitis, or indeterminate) whose previous anti-TNF medicine stopped working. It compares several newer treatments to see which works best.
This study creates a personalized medicine network to better understand and treat childhood arthritis. If you have JIA or unexplained joint inflammation, researchers will look at your biology to find the best treatment approach for you.
Hear when a new Polyarticular Course Juvenile Idiopathic Arthritis (JIA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.